Allergan Inc (AGN)
83.90USD
1 Jul 2013
$-0.34 (-0.40%)
$84.24
$85.33
$85.33
$83.76
2,463,612
2,755,439
$116.45
$81.28
AGN
About
Overall
| Beta: | 0.83 |
| Market Cap (Mil.): | $24,867.99 |
| Shares Outstanding (Mil.): | 296.40 |
| Dividend: | 0.05 |
| Yield (%): | 0.24 |
Financials
| AGN | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 22.44 | 32.92 | 33.02 |
| EPS (TTM): | 3.74 | -- | -- |
| ROI: | 14.42 | 19.76 | 19.07 |
| ROE: | 21.09 | 20.57 | 20.00 |
DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan
NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.
FDA draft guidance on generic eye drug push Allergen shares lower
WASHINGTON - Shares of Allergan Inc fell 12 percent on Monday after U.S. regulators issued draft guidance that would enable generic versions of the company's dry eye drug Restasis to come to market more quickly.
Allergan delays drug that would rival Regeneron's Eylea
- Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea
May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
Allergan delays eye drug, shares fall
- Allergan Inc , maker of the Botox anti-wrinkle treatment, said it will delay late-stage trials of its highly anticipated eye drug Darpin, sending its shares down 14 percent.
BRIEF-Regeneron Pharma shares resume trading, up 16 percent
NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval
BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3
NEW YORK, May 1 - Allergan Inc : * Resumes trading down 11.5 percent after company says phase 2 Darpin eye drug data does not support directly moving to phase 3
Strong Botox sales boost Allergan profit
- Allergan Inc , maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.
Strong Botox sales boost Allergan profit
May 1 - Allergan Inc, maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.
FDA staff says Allergan's new dermal filler effective
April 30 - Reviewers for the U.S. Food and Drug Administration said Allergan Inc's dermal filler, Juvéderm Voluma XC, was effective in correcting volume deficit in the middle of the face at six months of treatment.
Competitors
| Price | Change | |
|---|---|---|
| Alcon, Inc. (ACL.N) | -- | -- |
| Pfizer Inc. (PFE.N) | $27.78 | -0.23 |
| Novartis AG (NOVN.VX) | CHF67.00 | -0.30 |
| Merck & Co., Inc. (MRK.N) | $46.32 | -0.13 |
| Medicis Pharmaceutical Corp (MRX.N) | -- | -- |
| Johnson & Johnson (JNJ.N) | $86.63 | +0.77 |
| Obagi Medical Products, Inc. (OMPI.OQ) | -- | -- |
| L'oreal S.A (OREP.PA) | €126.90 | -1.30 |
| Actavis Inc (ACT.N) | $125.44 | -0.78 |
| Astellas Pharma Inc (4503.T) | ¥5,490 | +60.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (AGN). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
